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Summary
Background: Pakistan carries one of the world’s highest burdens of chronic hepatitis and
mortality due to liver failure and hepatocellular carcinomas. However, national level estimates
of the prevalence of and risk factors for hepatitis B and hepatitis C are currently not available.
Methods: We reviewed the medical and public health literature over a 13-year period (January
1994—September 2007) to estimate the prevalence of active hepatitis B and chronic hepatitis C in
Pakistan, analyzing data separately for the general and high-risk populations and for each of the
four provinces. We included 84 publications with 139 studies (42 studies had two or more sub-
studies).
Results: Methodological differences in studies made it inappropriate to conduct a formal meta-
analysis to determine accurate national prevalence estimates, but we estimated the likely range
of prevalence in different population sub-groups. A weighted average of hepatitis B antigen
prevalence in pediatric populations was 2.4% (range 1.7—5.5%) and for hepatitis C antibody was
2.1% (range 0.4—5.4%). A weighted average of hepatitis B antigen prevalence among healthy
adults (blood donors and non-donors) was 2.4% (range 1.4—11.0%) and for hepatitis C antibody was
3.0% (range 0.3—31.9%). Rates in the high-risk subgroups were far higher.
Conclusions: Data suggest a moderate to high prevalence of hepatitis B and hepatitis C in
different areas of Pakistan. The published literature on the modes of transmission of hepatitis B
and hepatitis C in Pakistan implicate contaminated needle use in medical care and drug abuse and
unsafe blood and blood product transfusion as the major causal factors.
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Hepatitis B virus (HBV) and hepatitis C virus (HCV) are
among the principal causes of severe liver disease, includ-
ing hepatocellular carcinoma and cirrhosis-related end-
stage liver disease. The World Health Organization (WHO)
estimates that there are 350 million people with chronic
HBV infection and 170 million people with chronic HCV
infection worldwide.1,2 Hepatitis B is estimated to result
in 563 000 deaths and hepatitis C in 366 000 deaths
annually.3 Given its large population (165 million) and
intermediate to high rates of infection,1,2 Pakistan is among
the worst afflicted nations.
Pakistan has one of the world’s highest fertility rates,
exceeding four children per woman.4 Its approximately
800 000 sq km are slightly less than twice the size of the
state of California in the USA and Pakistan is larger than
either Turkey or Chile.4,5 Pakistan is divided into four pro-
vinces, Punjab, Sindh, Northwest Frontier Province (NWFP),
and Balochistan, as well as federally administered areas
including the capital (Islamabad), Federally Administered
Tribal Areas (FATAs), and the western third of Jammu and
Kashmir.6,7 Considering Pakistan’s size and large, growing
population, there is a surprising dearth of information about
hepatitis prevalence, although more is known about its risk
factors. We reviewed the medical and public health litera-
ture over a 13-year period for details on the prevalence of
HBV and HCV in Pakistan, analyzing data separately for
general and high-risk populations and for each of the four
provinces. We further reviewed the published literature
concerning the risk factors, including the major modes of
transmission of HBV and HCV in Pakistan.
Methods
We initially identified the studies of interest from 1994 to
2007 (up to September 30, 2007) by search of the PubMed
database of the National Library of Medicine, National Insti-
tutes of Health (USA), using two search strategies: [hepatitis
AND Pakistan] and [(HBV OR HCV OR Blood Borne) AND
Pakistan]. We also searched in Pakmedinet.com, a search
engine that includes the non-indexed journals of Pakistan, by
using the keywords [hepatitis or HBV or HCV]. We identified
additional articles through searches of specific authors work-
ing in this field and through the cited references of relevant
articles.
Abstracts of 903 articles were reviewed by one author
(SAA) and 182 articles were identified based on the likelihood
that primary data on the prevalence of chronic HBVor HCV in
Pakistan were to be found within. Articles commenting on
risk factors for transmission of hepatitis in Pakistan were also
identified. Out of 182 articles, 23 could not be retrieved for
complete review due to the obscure or unclear nature of the
reference, though we included eight of these studies based
on the relevant information available in the abstracts. We
found 57 articles reporting primary data on the prevalence of
chronic HBV and 63 articles reporting primary data on the
prevalence of chronic HCV in Pakistan.
Detection of hepatitis B surface antigen (HBsAg) was
considered the marker of chronic HBV and detection of
hepatitis C virus antibody (HCVAb) was considered the mar-ker of chronic HCV. Data from these articles regarding study
time period, region (city and province), study population
(general or high-risk), lab techniques used for HBsAg or
HCVAb detection, total sample size, and percentages and
numbers of HBV and HCV positive cases were extracted.
Prevalence data from individual studies were further seg-
regated into age groups or regions of the country if described
in the study. Studies that included primarily but not exclu-
sively adult data were still grouped with adults. Some stu-
dies had methodological features that could be criticized;
they were included only if they provided the HBsAg or HCVAb
data on a defined population using reliable laboratory meth-
ods. Based on the sample size of individual studies, simple
Wilson binomial confidence intervals were calculated for
each study,8 alongwith a naı¨veweighted average prevalence
(weighted by each study’s sample size) in the general and
high-risk populations. Due to methodological differences
between studies and the very large sample sizes of a few
studies, no formal statistical testing for differences between
studies was carried out.
Results
HBV in general populations
Eight pediatric9—16 and 35 adult10,13,15,17—48 studies
addressed the seroprevalence of chronic HBV infection in
the general population of Pakistan using HBsAg in asympto-
matic persons. The weighted average of all the studies in
general pediatric populations was 2.4% (range 1.7—5.5%;
Figure 1). Studies in adults were either conducted in blood
bank donors17—37 or in a non-blood donor general popula-
tion.10,13,15,38—48 Overall HBsAg seroprevalence was higher in
the non-blood donor population (3.8% weighted average,
range 1.4—11.0%) than the blood donor population (2.3%
weighted average, range 1.4—8.4%; Figure 1). The overall
HBsAg seroprevalence in healthy adults based on combined
data from blood donors and non-donors was 2.4% (range 1.4—
11.0%).
Few studies have been published from Balochistan,15,39,43
NWFP,21,27,30,33,37,43,45 and rural parts of Sindh.18,48 Three
small studies in Balochistan15,39,43 showed a higher preva-
lence of HBsAg (9.3% weighted average, range 3.9—11.0%)
compared to other provinces (Figure 1). Wide variations in
different areas within each province were again noted but no
clear trends in prevalence rates were identified over time.
HCV in general populations
We found eight pediatric9,10,14,16,38,49—51 and 35
adult10,17,18,22—25,27—30,32—38,40—42,44—47,49,50,52—59 studies
assessing HCVAb seroprevalence in general populations.
The weighted average HCVAb seroprevalence in
pediatric studies was 2.1% (range 0.4—5.4%). In the
adults, studies of HCV seroprevalence in non-blood
donors10,38,40—42,44—47,49,50,59 showed higher rates (5.4%
weighted average, range 2.1—31.9%) than in blood
donors17,18,22—25,27—30,32—37,52—58 (2.8% weighted average,
range 0.3—20.7%; Figure 2). The overall HCV seroprevalence
in healthy adults, based on combined data from blood donors
and non-donors was 3.0% (range 0.3—31.9%).
Figure 1 Summary of studies reporting HBV prevalence in the general population of Pakistan. Each study is represented horizontally.
From left to right: reference number, first author, city in which the study was conducted, year in which the study was published; dot and
bar represent the point prevalence of HBV with calculated 95% confidence interval; lab technique used to detect hepatitis B surface
antigen (HBsAg); sample size of the study. The vertical line represents the calculated weighted average prevalence of HBV based on all
the studies in the particular group.
ELISA, enzyme-linked immunosorbent assay (number represents generation of test); RPHA, reverse particle hemagglutination assay;
ICT, immunochromatographic test; LPA, latex particle agglutination; MEIA, micro-enzyme immunoassay (number represents genera-
tion of test); RIBA, recombinant immunoblot assay; ??, unknown.
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reports suggested a higher prevalence of HCV (4.3% weighted
average, range 0.4—31.9%) compared to Sindh,18,22,32,45,52,56
Balochistan,55 and NWFP27,30,33,37,45,59 (Figure 2).
Ten10,38,40—42,44,46,47,49,50 of 12 studies10,38,40—42,44—47,49,50,59
in non-blood donors were performed in Punjab. Wide varia-
tions in different areas within Punjab were noted (range 0.4—
31.9%) and no clear trends were identified over time.Prevalence of HBV and HCV in high-risk
populations
Few studies have addressed the prevalence of HBsAg and
HCVAb in the high-risk populations of Pakistan60—93(Figure 3).
Only one study in female sex workers67 and one study in male
sex workers (hijras, some of whom are eunuchs)68 were found
to address the HBV seroprevalence in this population
(Figure 3). No HCV study in sex workers was identified.
Studies in the household contacts of HCV infectedpatients60—66 showed a relatively high prevalence of HCV
(19.0% weighted average, range 4.3—38.0%; Figure 3). In
multi-transfused population of patients with thalassemia
or hemophilia, three studies71,72,75 showed a moderately
high prevalence of HBsAg (7.8% weighted average, range
5.0—8.4%), while seven studies69—75 showed a very high
prevalence of HCVAb (47.2% weighted average, range 25—
60%; Figure 3). Similarly, a high prevalence of HBsAg83,84
(14.6% weighted average, range 12.4—16.6%) and HCVAb85,86
(38% weighted average, range 23.7—68%) was described in
the studies of patients undergoing chronic dialysis. Studies
in healthcare workers showed relatively higher rates of
HBV76—82 (6% weighted average, range 0—10.3%) and
HCV79,81,82 (5.5% weighted average, range 4.0—5.9%,
Figure 3) than in the general population (Figures 1 and 2).
Studies in pregnant women showed similar rates of HBV87—89
(2.9% weighted average, range 1.8—12.6%; Figure 3), but
higher rates of HCV89—93 (5.3% weighted average, range
3.2—16.5%; Figure 3), compared to the general population
(Figures 1 and 2).
Figure 2 Summary of studies reporting HCV prevalence in the general population of Pakistan. Each study is represented horizontally.
From left to right: reference number, first author, city in which the study was conducted, year in which the study was published; cross
and bar represent the point prevalence of HCV with calculated 95% confidence interval; lab technique used to detect hepatitis C virus
antibody (HCVAb); sample size of the study. The vertical line represents the calculated weighted average prevalence of HCV based on
all the studies in the particular group.
ELISA, enzyme-linked immunosorbent assay (number represents generation of test); RPHA, reverse particle hemagglutination assay;
ICT, immunochromatographic test; LPA, latex particle agglutination; MEIA, micro-enzyme immunoassay (number represents genera-
tion of test); RIBA, recombinant immunoblot assay; ??, unknown.
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Needles in healthcare settings
Injections in healthcare settings have been well described in
the literature as a major mode of transmission of HBV and
HCV in developing countries.94,95 A few well-controlled stu-
dies have demonstrated a relationship between therapeutic
injections and thehighprevalenceofHBVandHCV.14,38,60,96—99
Khan et al. interviewed 203 adult patients as they left local
clinics in a peri-urban community just outside of Karachi
(Sindh), the major port city located in southern Pakistan.96
Of the patients, 81% received an injection on the day of
interview. Of the 135 patients who provided a serum sample,
44%were HCVAb positive and 19% had antibodies against HBV
(HBsAg was not measured). If oral and injectable medica-
tions were deemed equally effective, 44% of the patients
declared that they would still prefer injectables. Unsterile,
used needles were being used in 94% of the injections
observed by the study team and none of the 18 practitioners
knew that HCV could be transmitted by injections. In a case—control study in Hafizabad (Punjab), Luby et al. found that
HCV infected patients were significantly more likely to have
received five or more injections in the past 10 years com-
pared to non-infected controls (odds ratio 5.4, confidence
interval 1.2—28).38 In a study of household members of
patients with HCV in Hafizabad (Punjab), Pasha et al. showed
that the household members who had more than four injec-
tions per year were 11.9 times more likely to be infected
than others ( p = 0.02).60 Similarly, Usman et al. found that in
patients with acute HBV, the attributable risk for therapeu-
tic injections was 53%.97 Other studies by Jafri et al., Bari
et al., Shazi and Abbas, and others have also shown similar
results from diverse regions of Pakistan.14,98,99
Luby et al. in a follow-up study in Hafizabad showed that it
is possible to improve the practice of unsterile and unneces-
sary injections by relatively simple community-based inter-
ventions.100 After low-cost community-based efforts to
increase awareness, there was a reported decrease in the
use of injections overall and an increase in the use of new
needles for injections. The assumption that this will lead to
Figure 3 Summary of studies reporting HBV and HCV prevalence in the high-risk population of Pakistan. Each study is represented
horizontally. From left to right: reference number, first author, city in which the study was conducted, year in which the study was
published; dot and bar represent the point prevalence of HBV with calculated 95% confidence interval while cross and bar represent
point prevalence of HCV with calculated 95% confidence interval; lab technique used to detect hepatitis B surface antigen (HBsAg) or
hepatitis C virus antibody (HCVAb); sample size of the study. The vertical line represents the calculated weighted average prevalence
of HBV or HCV based on all the studies in the particular group.
ELISA, enzyme-linked immunosorbent assay (number represents generation of test); RPHA, reverse particle hemagglutination assay;
ICT, immunochromatographic test; LPA, latex particle agglutination; MEIA, micro-enzyme immunoassay (number represents genera-
tion of test); RIBA, recombinant immunoblot assay; ??, unknown.
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but has not been demonstrated.
Receipt of blood and blood products
Very high prevalence rates of HBV and HCV in multi-trans-
fused populations are due to blood transfusions, but limited
data are available about the practices of blood banks in
Pakistan. Luby et al. studied 24 randomly selected blood
banks in Karachi in 1995; while 95% had reagents and equip-
ment to test for HBV, only 55% could screen for HIVand 23% for
HCV.101 Fifty percent of blood banks regularly utilized paid
blood donors and only 25% actively recruited voluntary blood
donors. More recent data about the practices are not avail-
able. In 2001, Ahmed reported a higher prevalence of HBV in
professional blood donors as compared to voluntary blood
donors (9% vs. 0.8%, p < 0.001).102
Injection drug users (IDUs)
According to the year 2000 National Assessment Study of Drug
Use in Pakistan supported by the United Nations Office of
Drug Control and Crime Prevention (UNODC), there are
500 000 heroin addicts in Pakistan, of whom 75 000 (15%)
are regular IDUs and 150 000 (30%) are occasional IDUs.103
Data on the disease burden in this large high-risk population
are limited. Kuo et al., in a study conducted in 2003, showed
HCV prevalence of 93% and 75% among IDUs of Lahore (Pun-
jab) and Quetta (Balochistan), respectively,104 while Achak-zai et al., in a smaller study in 2004, showed HBV, HCV, and
HIV prevalences of 6%, 60%, and 24%, respectively, in the IDUs
of Quetta.105 A year 2005 pilot survey of IDUs in Karachi
(Sindh) showed an HIV prevalence of 26%, confirming the
long-anticipated expansion of the HIV epidemic in Paki-
stan.106 HBV and HCV seroprevalence rates were not studied
in this survey. A follow-up national survey in 2005 showed HIV
prevalence of 23% and 0.5% and HCV prevalence of 88% and
91% in IDUs of Karachi (Sindh) and Lahore (Punjab), respec-
tively.107
Occupational risks
Certain professions like healthcare workers, sex workers, and
barbers may be at increased risk of getting HBV and HCV. The
best studied amongst them in Pakistan are healthcare work-
ers, showing a relatively higher prevalence (weighted aver-
age 6% and 5.5% for HBV and HCV, respectively) than in
general population (Figures 1 and 2). The lack of universal
immunization against HBV has been highlighted, especially in
these high-risk populations, but coverage of HBV immuniza-
tion has improved in the general population since 2003.108
According to the WHO—UNICEF estimates of 2005, 73% of the
target population (infants <1 year) of Pakistan have been
vaccinated for HBV.108 While trends are encouraging, cover-
age is still significantly lower than in industrialized countries.
Its benefits on HBV incidence may not be apparent for many
years, though eventually one would expect substantial
14 S.A. Ali et al.benefit from the innovation of HBV vaccination among Pakis-
tani infants.
Shaving by barbers
It has been suspected that barbers may be contributing to the
spread of HBV and HCV by using contaminated razors for
shaving. Janjua and Nizamy, in a cross-sectional study of
barbers in Rawalpindi/Islamabad in 1999, showed that only
13% knew that hepatitis could be transmitted by contami-
nated razors.109 During the actual observation, razors were
reused for 46% of shaves. It is possible that contaminated
razors may be contributing in the transmission of HBV and
HCV, but their relative importance is not clear.
Household contacts/spousal transmission
While some studies have shown a relatively higher prevalence
in the household members of patients with HBV and HCV,
other studies in the spouses of index cases have shown rates
similar to controls.60—64 Pasha et al. showed the prevalence
of HCV in household members of HCV patients to be 2.5 times
that of the general population, but no routes of transmission
within the household were associated.60 The international
literature suggests that the sexual transmission of HCV is very
low.110,111 It is likely that the high prevalence reported in
household contacts in Pakistan may be due to the fact that
they are exposed to the same community risk factors as the
index patient, rather than intra-household transmission per
se. In contrast, HBV intra-familial transmission is well docu-
mented outside of Pakistan, and HBV is far more infectious as
compared to HCV or HIV.112—114
Discussion
We observed highly variable seroprevalence estimates for
both HBV and HCV from different studies in similar popula-
tions, even within the same province. Unlike highly conta-
gious diseases like measles that have a more predictable
seroprevalence, blood-borne illnesses like hepatitis and HIV
are transmitted sporadically or in micro-epidemics. These
micro-epidemics may account for the wide variations in
prevalence seen within a nation, a province, or even a
community. Identification of the causes of these micro-epi-
demics provides an opportunity to limit the transmission of
these diseases.115—117 However, methodological differences
in sampling strategies may also contribute to differences in
seroprevalence within similar regions or populations. For
example, one study of the general population did a staged
cluster random sampling of the entire city’s study popula-
tion,14 while another study of putative ‘random samples’ in a
different city recruited persons with the aid of newspaper
advertisements50 that may have distorted the risk profile of
respondents compared to the former study.
As seen in this review, studies of HBV and HCV prevalence
are often conducted in blood donor populations because of
convenience and access to a large sample size. However,
these studies may not truly represent the general population.
Prevalence in blood donors may be an underestimate of the
population prevalence if potential donors with a high-risk
profile, like history of jaundice, injection drug use, multiple
sexual partners, etc. are screened out by questionnaires.
Conversely, prevalence in blood donors may be an overesti-mate of the general population if professional blood donors
were included, who are often injection drug users selling
blood for money. Nonetheless, it is clear that both HBV and
HCV infections are very common in Pakistan such that serious
incidence rates of end-stage liver disease, both cirrhosis and
hepatocellular carcinoma, will plague this nation for many
years to come.
The published literature regarding risk factors for HBVand
HCV transmission in Pakistan is informative. WHO estimates
that in Southeast Asia, an average person receives four
injections per year, most of which are unnecessary and up
to 75% are unsafe or reused.118 Unnecessary injections are
given commonly in Pakistan out of the prevalent view in the
population that injected medicines are more effective than
oral medications.119,120 Intramuscular injections are fre-
quently used for fever, fatigue, and general ailments, while
intravenous drips are used for the treatment of weakness,
fever, and ‘severe’ diseases.96,120,121 Some people use IV
drips to cool down during the summer (HQ, personal observa-
tion). These injections are given by physicians at clinics, by
informal, untrained providers, by health workers who do
home visits, and by pharmacists both trained and infor-
mal.122,123 The healthcare providers may even encourage
the injection-seeking behavior because patients are more
willing to pay an additional physician’s fee for injections but
will not pay this added fee for oral medications.123 Syringes
are reused and sterility of injections is often not maintained
due to financial limitations and lack of risk awareness among
the healthcare providers and the population in general.122
These injections appear to be the single most significant
factor in the spread of HBVand HCV in the general population
of Pakistan.
There are about 1.5 million units of blood products
transfused each year in Pakistan.124 Data on the safety of
this transfusion process are scanty — perhaps due to the
lack of a system of reporting infectious or non-infectious
adverse events.125 The transfusion network is poorly orga-
nized and likely contributes significantly in the transmission
of serious infectious diseases. In fact, the leading hepatol-
ogist and public health scientist of Pakistan and editor of
the country’s premier medical journal for 30 years died in
2004 of cerebral malaria that she acquired through a blood
transfusion given during bilateral knee replacement sur-
gery. Her case dramatized the need for regulation and
control of the transfusion practices in Pakistan. Under
the umbrella of National Blood Policy, comprehensive mea-
sures are needed in both public and private sectors of all
four provinces. These measures should include a situational
analysis and a realistic assessment of the blood require-
ment in the area, followed by recruitment and mainte-
nance of voluntary, non-remunerated blood donors and
standardization and regulation of appropriate blood
screening procedures.
IDUs are numerous in Pakistani society and though they
have a disproportionately high burden of health problems,
they have been inadequately studied. Limited data suggest
the likelihood that the prevalences of hepatitis and HIV are
very high in this community. Urgent efforts need to be made
to better study this population and to apply globally effective
programs like needle exchange and condom distribution
together with appropriate counseling and therapy for their
drug addiction. Unless serious infections are controlled in
Table 1 Suggested interventions for reducing the transmission of blood-borne infections in Pakistan in addition to HBV vaccination
Risk factor Structural level interventions Health provider level interventions Individual level interventions
Injections in healthcare
settings
 Media campaign to educate public about
risks of unnecessary injectionsCounseling
of discordant couples in condom use
Education regarding: Counseling for:
 Availability of low-cost, single use syringes  Risks of unnecessary injections  Insistence on oral medications whenever possible
 Ensure availability of low-cost oral medicines  Risks of reuse of needles  Insistence on only new syringes and
needles for injections Availability of oral medication
alternatives to injectables
Injection drug use  Creation of positive opportunities for youth Training regarding:  Education of the addict regarding the risks
of infections caused by sharing needles
 Recognition of the problem in the community  Recognition of signs of drug
abuse and the need to screen
for HBV, HCV, and HIV
 Counseling of the addict’s family
to support the patient
 Needle exchange programs/single use syringes only  Counseling, treatment, and
rehabilitation of drug addicts
 Limit availability of drugs  Stigma reduction and willingness
to care for addicts Drug treatment programs with opiate agonist availability
Receipt of blood and
blood products
 Enforcement of legislation regarding
mandatory screening of blood at all blood banks
Education regarding: Family education regarding:
 Media campaign to encourage volunteer
blood donations
 Importance of comprehensive
screening of all blood products
 Risks of paid blood donations
 Ban on paid blood donations  Dangers associated with paid
blood donations
 Insistence on well-screened blood only
 Limited indications for transfusion
to avoid overuse
 Avoidance of unnecessary use of blood
or blood products
Occupational risk to
healthcare workers
 Availability of safer injection
technologies for blood drawing
Education regarding: Education regarding:
 Proper disposal of contaminated waste  Safety precautions  Safety precautions
 Management of high-risk situations  Hand washing
Prevention of mother
to child transmission
 Universal prenatal screening
policies for HBV and HIV
Education regarding:  Mass education regarding
benefits of HBV and HIV screening
 Ready availability of test kits,
drugs, vaccines, and immune globulin
 Need for universal screening  Counseling for reduction in social harm
 Management of HIV with antiretroviral
medications and replacement or
exclusive breast feeding
 Management of HBV with vaccine
and HepB immune globulin in neonates
Sexual transmission  100% condom policy in sex industry Education regarding:  Education of sex workers regarding condom use
 ‘ABC’ advocacy and education  Management of STDs  Counseling of discordant
couples in condom use Expanded STD services  ‘ABC’
 Stigma reduction and willingness
to care for at-risk population
HBV, hepatitis B virus; HCV, hepatitis C virus; STD, sexually transmitted disease; ABC, ‘Abstinence’ for youth, ‘Be faithful’ for sexually active, and ‘Condom availability and education’ specially for high-risk
persons and venues.
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16 S.A. Ali et al.IDUs, they will continue to be the source of HBV, HCV, and
now HIV to the general population in Pakistan.
While universal immunization against HBV has still not
been achieved, significant advances have been made. HBV
vaccine has been included in the EPI (Expanded Program for
Immunization) since 2002. All healthcare providers in the
public sector are eligible for free HBV vaccination. Full
coverage with HBV vaccination in the general population
would be ideal, but at least healthcare workers and other
high-risk professionals should be immunized universally.
The Herculean task of reeducating healthcare providers,
informal sector providers, high-risk persons, and the general
population is worthy of investment, particularly now that HIV
has risen markedly among IDUs, resulting in a concentrated,
rather than a nascent epidemic.106,107 Urgent comprehensive
efforts at the structural, healthcare provider, and individual
level are needed to control the spread of these blood-borne
infections (Table 1).
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